LyophilisedCAGS
CagriSema
Bulk≥99.5% Purity
Pharmaceutical-grade CagriSema combination for dual amylin + GLP-1 weight management therapy.
Request a Quote
Pricing available for qualified medical professionals, clinics, and distributors.
Enquire NowDownload MonographView FAQMechanism of Action
CagriSema combines cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist) in a fixed ratio. This dual-pathway approach activates both amylin and GLP-1 receptors simultaneously, producing additive appetite suppression and metabolic effects beyond what either agent achieves alone.
Clinical Benefits
- Dual amylin + GLP-1 receptor activation
- Enhanced weight reduction vs monotherapy
- Demonstrated up to 25% body weight reduction in trials
- Synergistic appetite suppression mechanisms
Specifications
ComponentsCagrilintide + Semaglutide
MechanismDual amylin + GLP-1
Purity≥99.5% (each component)
Storage & Handling
- Store at 2–8°C
- Protect from light
For professional medical use only. Not for retail sale to the general public. Pricing available on request for qualified medical institutions and distributors.